Aim:

To investigate the risk factors for prostatic inflammation extent and infection in patients with benign prostatic hyperplasia (BPH) so as to manage prostatic inflammation more efficiently.

Methods:

Sixty patients with BPH undergoing TURP between September 2005 and December 2005 in West China Hospital of Sichuan University were studied. Prostate fluid (PF) was collected for the measurement of secretory IgA (SIgA) and complement 3 (C3). Prostate tissue were collected for testing bacterial 16S rDNA by real-time PCR, examining SIgA in the tissue and examining the inflammation. The possible clinical and immune risk factors for prostatic inflammation or infection were analyzed by using the logistic regression method.

Results:

Abnormal white blood cell count in urinalysis, prostatic infection and a high concentration of C3 in PF are the risk factors for prostatic inflammation extent (P = 0.025, 0.034 and 0.035, respectively and odds ratio [OR] = 18.269, 8.284 and 1.508, respectively). Risk factors for prostatic infection include the C3 concentration and the concentration of SIgA in PF (P = 0.003 and 0.013, respectively, and OR = 1.645 and 0.993, respectively).

Conclusion:

The present study suggests that prostatic inflammation is associated with urinary tract infection, prostatic infection and the activated complement and that prostatic infection is associated with the activated complement and downregulated mucosal immunity in prostates of the patients with BPH. It is also suggested that individual immune regulation should be considered in the treatment of prostatic inflammation and infection of patients with BPH.

References

1. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976–81. | Article | PubMed | ChemPort |
2. Roehrborn CG, Kaplan SA, Noble WD, Lucia MS, Slawin KM, McVary K, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. 2005 AUA meeting. J Urol 2005; 173 (Suppl 4): 346. | ISI |
3. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004; 61: 60–72. | Article | PubMed | ChemPort |
4. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26: 1170–81. | Article | PubMed | ISI | ChemPort |
5. Qiang W, Jianchen W, MacDonald R, Monga M, Wilt TJ. Antibiotic prophylaxis for transurethral prostatic resection in men with preoperative urine containing less than 100,000 bacteria per mL: a systematic review. J Urol 2005, 173: 1175–81. | Article | PubMed |
6. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician 2005; 71: 1153–62. | PubMed |
7. Takahashi S, Riley DE, Krieger JN. Application of real-time polymerase chain reaction technology to detect prostatic bacteria in patients with chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2003; 21: 100–4. | Article | PubMed | ChemPort |
8. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87: 797–805. | Article | PubMed | ChemPort |
9. Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 2005; 174: 1231–7. | Article | PubMed |
10. Zackrisson B, Ulleryd P, Aus G, Lilja H, Sandberg T, Hugosson J. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology 2003; 62: 278–81. | Article | PubMed |
11. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164–75. | Article | PubMed |
12. He C, Imai M, Song H, Quigg RJ, Tomlinson S. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol 2005; 174: 5750–7. | PubMed | ISI | ChemPort |
13. Lawson AJ. Discovering new pathogens: culture-resistant bacteria. Methods Mol Biol 2004; 266: 305–22. | PubMed | ChemPort |
14. Dai YP, Sun XZ, Zheng KL. Endotoxins in the prostatic secretions of chronic prostatitis patients. Asian J Androl 2005; 7: 45–7. | Article | PubMed |
15. Ferguson JS, Weis JJ, Martin JL, Schlesinger LS. Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect Immun 2004; 72: 2564–73. | Article | PubMed | ChemPort |
16. Dominguez M, Moreno I, Aizpurua C, Torano A. Early mechanisms of Leishmania infection in human blood. Microbes Infect 2003; 5: 507–13. | Article | PubMed | ChemPort |
17. Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med 2001; 7: 801–6. | Article | PubMed | ISI | ChemPort |
18. Suman E, Gopalkrishna Bhat K, Hegde BM. Bacterial adherence and immune response in recurrent urinary tract infection. Int J Gynaecol Obstet 2001; 75: 263–8. | Article | PubMed | ChemPort |
19. Bene MC, Studer A, Faure G. Immunoglobulin-producing cells in human prostate. Prostate 1988; 12: 113–7. | Article | PubMed | ChemPort |